SIRP-α/β1 Antibody (A-1): sc-376220

SIRP-α/β1 Antibody (A-1) is a mouse monoclonal IgG1 antibody that detects SIRP-α/β1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). SIRP-α/β1 is part of the signal-regulatory protein family, which plays a crucial role in modulating immune responses and cellular signaling pathways. Specifically, SIRP-α is a transmembrane protein characterized by its extracellular domain containing three immunoglobulin-like structures and a cytoplasmic region with multiple tyrosine phosphorylation sites. This structural configuration allows SIRP-α to interact with various receptor tyrosine kinases, thereby influencing cellular responses to growth factors and oncogenes. The phosphorylation of SIRP-α enables binding to SH-PTP2, a protein-tyrosine phosphatase, through SH2 domain interactions, which further enhances a role in negatively regulating signaling pathways such as the PI 3-kinase pathway. This regulation is vital for controlling cell motility and survival, particularly in the context of cancer transformation. Additionally, SIRP-β1, which shares extensive homology with SIRP-α, lacks the cytoplasmic domain, indicating a divergence in function and regulatory mechanisms within the SIRP family. SIRP-α/β1 (A-1) antibody serves as an essential tool for researchers investigating the complex interactions and regulatory roles of these proteins in human health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SIRP-α/β1 Antibody (A-1) References:

1. SIRPbeta1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration.  |  Liu, Y., et al. 2005. J Biol Chem. 280: 36132-40. PMID: 16081415
2. OX130 Monoclonal Antibody Recognizes Human SIRPβ1 but Cross-Reacts on SIRPα from One Allele.  |  Hatherley, D., et al. 2016. Monoclon Antib Immunodiagn Immunother. 35: 57-9. PMID: 26871367
3. Cancer immunotherapy targeting the CD47/SIRPα axis.  |  Weiskopf, K. 2017. Eur J Cancer. 76: 100-109. PMID: 28286286
4. Measles virus nucleocapsid protein modulates the Signal Regulatory Protein-β1 (SIRPβ1) to enhance osteoclast differentiation in Paget's disease of bone.  |  Sundaram, K., et al. 2017. Bone Rep. 7: 26-32. PMID: 28840181
5. Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy.  |  Uger, R. and Johnson, L. 2020. Expert Opin Biol Ther. 20: 5-8. PMID: 31663384
6. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.  |  Sakamoto, M., et al. 2022. Proc Natl Acad Sci U S A. 119: PMID: 34949714
7. The CD47-SIRPα axis is a promising target for cancer immunotherapies.  |  Hao, Y., et al. 2023. Int Immunopharmacol. 120: 110255. PMID: 37187126
8. An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response.  |  García-Alberca, JM., et al. 2024. J Alzheimers Dis. 98: 601-618. PMID: 38427484
9. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.  |  Jin, S., et al. 2024. Cell Commun Signal. 22: 173. PMID: 38462636
10. CD47-SIRPα Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells.  |  Li, B., et al. 2024. Cancer Res. 84: 3189-3206. PMID: 38959336

The preferred SIRP-α antibody is SIRP-α Antibody (SE7C2): sc-23863.